EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Effect of Individual and Combined Cytochrome P450 Activity Scores on Symptom Improvement and Side Effects in Youth Treated With Sertraline

Samuel Gerlach, Abdullah Al Maruf iD, Sarker M Shaheen iD, Ryden McCloud, Madison Heintz iD, Laina McAusland iD, Paul D Arnold iD, Chad A Bousman iD

Clinical and Translational Science · 2026-05 · 19 (5)

DOI: 10.1111/cts.70590 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 11.05.2026. Verfasst von Samuel Gerlach und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Sertraline, Cytochrome P-450 Enzyme System, Selective Serotonin Reuptake Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Alberta Children's Hospital Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sertraline is commonly used to treat mental health conditions in youth. However, its tolerability and efficacy vary between individuals, partly due to interindividual differences in drug metabolism. This study assessed the individual and combined impact of genetic variation in cytochrome P450 drug‐metabolizing enzymes on patient‐reported side effects and symptom improvement in 347 youth, aged 6–24, receiving sertraline treatment. Participants reported sertraline dose, duration, adherence, concomitant medications, side effects, and symptom improvement. DNA was extracted from saliva samples and genotyped for CYP2B6 , CYP2C9 , CYP2C19 , CYP2D6 , and CYP3A4 . Individual activity scores and a weighted combinatorial CYP450 activity score were created. Binomial logistic regression models were used to assess the impact individual and combined CYP450 activity scores had on patient‐reported side effects and symptom improvement, both with and without correction for phenoconversion. After adjusting for phenoconversion, other CYP450 activity scores, and covariates, higher activity scores for CYP2D6 (OR = 0.288, 95% CI = 0.091–0.913) and CYP3A4 (OR = 0.002, 95% CI = 0.001–0.375) were nominally associated with reduced odds of symptom improvement. A higher combined CYP450 activity score was associated with reduced odds of symptom improvement (OR = 0.060, 95% CI = 0.004–0.797) and side effects (OR = 0.097, 95% CI = 0.010–0.925). These findings suggest that a combined CYP450 activity score may serve as a marker of symptom improvement and side effects in youth, but validation using sertraline/desmethylsertraline concentrations is required. If validated, these results may inform updates to pharmacogenetic prescribing guidelines for sertraline and support more personalized sertraline use in youth.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SertralineCytochrome P-450 Enzyme SystemSelective Serotonin Reuptake InhibitorsHumansAdolescentFemaleChildMaleYoung AdultTreatment OutcomeTreatment Effect HeterogeneityPharmacogenomic VariantsCytochrome P-450 CYP2D6

Stichwörter der Autor:innen

adolescentschildrenemerging adultspharmacogeneticspsychiatrysertraline

Substanzen

SertralineCytochrome P-450 Enzyme SystemSelective Serotonin Reuptake InhibitorsCytochrome P-450 CYP2D6

Autor:innen und Institutionen

  • Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Children's Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada.
  • The Mathison Centre for Mental Health Research & Education, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada.
  • Department of Medical Genetics, University of Calgary, Calgary, Alberta, Canada.

ORCID-Profile: Abdullah Al Maruf, Sarker M Shaheen, Madison Heintz, Laina McAusland, Paul D Arnold, Chad A Bousman

Förderung

  • Alberta Children's Hospital Foundation

Zitieren

APA

Gerlach, S., Maruf, A. A., Shaheen, S. M., McCloud, R., Heintz, M., McAusland, L., Arnold, P. D., & Bousman, C. A. (2026). Effect of Individual and Combined Cytochrome P450 Activity Scores on Symptom Improvement and Side Effects in Youth Treated With Sertraline. Clinical and Translational Science, 19(5). https://doi.org/10.1111/cts.70590

Vancouver

Gerlach S, Maruf AA, Shaheen SM, McCloud R, Heintz M, McAusland L, et al. Effect of Individual and Combined Cytochrome P450 Activity Scores on Symptom Improvement and Side Effects in Youth Treated With Sertraline. Clinical and Translational Science. 2026;19(5). doi:10.1111/cts.70590

BibTeX
@article{Gerlach2026,
  author = {Gerlach, Samuel and Maruf, Abdullah Al and Shaheen, Sarker M and McCloud, Ryden and Heintz, Madison and McAusland, Laina and Arnold, Paul D and Bousman, Chad A},
  title = {Effect of Individual and Combined Cytochrome P450 Activity Scores on Symptom Improvement and Side Effects in Youth Treated With Sertraline},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {5},
  doi = {10.1111/cts.70590}
}
Kostenlos starten →